Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up

Donizy,Piotr; Halon,Agnieszka; Surowiak,Pawel; Kaczorowski,Maciej; Kozyra,Cyprian; Matkowski,Rafal

doi:10.3892/ol.2016.4890

Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up

Authors:
- Piotr Donizy
- Agnieszka Halon
- Pawel Surowiak
- Maciej Kaczorowski
- Cyprian Kozyra
- Rafal Matkowski
View Affiliations

Affiliations: Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wroclaw 50‑556, Poland, Department of Histology and Embryology, Wroclaw Medical University, Wroclaw 50‑556, Poland, Department of Statistics, Wroclaw University of Economics, Wroclaw 53‑345, Poland, Department of Oncology and Surgical Oncology, Wroclaw Medical University, Wroclaw 50‑556, Poland
Published online on: July 20, 2016 https://doi.org/10.3892/ol.2016.4890
Pages: 1667-1674
Copyright: © Donizy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polo-like kinase 1 (PLK1) is a serine-threonine kinase that plays a crucial role in the regulation of cell division. In addition, it acts as a modulator of the DNA damage response and as a novel factor in the maintenance of genome stability during DNA replication. The present study aimed to reveal the associations between PLK1 expression and clinicopathological features of patients with breast cancer (BC), particularly patient survival at 5‑, 10‑ and 15‑year follow‑up. PLK1 expression was evaluated immunohistochemically in routine diagnostic tissue specimens from 83 patients treated radically for stage II BC. Kaplan‑Meier analysis revealed a correlation between PLK1 overexpression and long‑term survival. High PLK1 immunoreactivity was associated with shorter cancer‑specific overall survival (CSOS) and disease‑free survival (P=0.00001 and 0.00013, respectively). Multivariate analysis confirmed the negative prognostic significance of PLK1 overexpression for CSOS in all 83 patients (P=0.00030). Furthermore, analogous correlations were observed in both subgroups with and without nodal metastases (P=0.01400 and 0.01200, respectively). The present results indicate that PLK1 expression has a prognostic role in early BC. Immunohistochemical assessment of PLK1 reactivity may potentially become a qualifier for inclusion of PLK1 inhibitor therapy.

View Figures

View References

1	Glover DM, Hagan IM and Tavares AA: Polo-like kinases: A team that plays throughout mitosis. Genes Dev. 12:3777–3787. 1998. View Article : Google Scholar : PubMed/NCBI
2	Andrysik Z, Bernstein WZ, Deng L, Myer DL, Li YQ, Tischfield JA, Stambrook PJ and el Bahassi M: The novel mouse polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res. 38:2931–2943. 2010. View Article : Google Scholar : PubMed/NCBI
3	de Cárcer G, Escobar B, Higuero AM, García L, Ansón A, Pérez G, Mollejo M, Manning G, Meléndez B, Abad-Rodríguez J and Malumbres M: Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol. 31:1225–1239. 2011. View Article : Google Scholar : PubMed/NCBI
4	de Cárcer G, Manning G and Malumbres M: From Plk1 to Plk5: Functional evolution of polo-like kinases. Cell Cycle. 10:2255–2262. 2011. View Article : Google Scholar : PubMed/NCBI
5	Seeburg DP, Pak D and Sheng M: Polo-like kinases in the nervous system. Oncogene. 24:292–298. 2005. View Article : Google Scholar : PubMed/NCBI
6	Hansen DV, Loktev AV, Ban KH and Jackson PK: Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell. 15:5623–5634. 2004. View Article : Google Scholar : PubMed/NCBI
7	Golsteyn RM, Mundt KE, Fry AM and Nigg EA: Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol. 129:1617–1628. 1995. View Article : Google Scholar : PubMed/NCBI
8	Lane HA and Nigg EA: Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 135:1701–1713. 1996. View Article : Google Scholar : PubMed/NCBI
9	Petronczki M, Glotzer M, Kraut N and Peters JM: Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Dev Cell. 12:713–725. 2007. View Article : Google Scholar : PubMed/NCBI
10	Lowery DM, Lim D and Yaffe MB: Structure and function of Polo-like kinases. Oncogene. 24:248–259. 2005. View Article : Google Scholar : PubMed/NCBI
11	van Vugt MA and Medema RH: Getting in and out of mitosis with Polo-like kinase-1. Oncogene. 24:2844–2859. 2005. View Article : Google Scholar : PubMed/NCBI
12	Takai N, Hamanaka R, Yoshimatsu J and Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene. 24:287–291. 2005. View Article : Google Scholar : PubMed/NCBI
13	Takaki T, Trenz K, Costanzo V and Petronczki M: Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Opin Cell Biol. 20:650–660. 2008. View Article : Google Scholar : PubMed/NCBI
14	el Bahassi M: Polo-like kinases and DNA damage checkpoint: Beyond the traditional mitotic functions. Exp Biol Med (Maywood). 236:648–657. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, Hieter P and Todokoro K: PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol Cell. 1:371–380. 1998. View Article : Google Scholar : PubMed/NCBI
16	Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32. 2001. View Article : Google Scholar : PubMed/NCBI
17	Bartek J and Lukas J: DNA damage checkpoints: From initiation to recovery or adaptation. Curr Opin Cell Biol. 19:238–245. 2007. View Article : Google Scholar : PubMed/NCBI
18	Macůrek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB and Medema RH: Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature. 455:119–123. 2008. View Article : Google Scholar : PubMed/NCBI
19	Seki A, Coppinger JA, Jang CY, Yates JR and Fang G: Bora and the kinase Aurora A cooperatively activate the kinase Plk1 and control mitotic entry. Science. 320:1655–1658. 2008. View Article : Google Scholar : PubMed/NCBI
20	van Vugt MA, Brás A and Medema RH: Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell. 15:799–811. 2004. View Article : Google Scholar : PubMed/NCBI
21	Mamely I, van Vugt MA, Smits VA, Semple JI, Lemmens B, Perrakis A, Medema RH and Freire R: Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Curr Biol. 16:1950–1955. 2006. View Article : Google Scholar : PubMed/NCBI
22	Holtrich U, Wolf G, Bräuninger A, Karn T, Böhme B, Rübsamen-Waigmann H and Strebhardt K: Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA. 91:1736–1740. 1994. View Article : Google Scholar : PubMed/NCBI
23	Jang YJ, Kim YS and Kim WH: Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Int J Oncol. 29:589–594. 2006.PubMed/NCBI
24	Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 94:148–152. 2003. View Article : Google Scholar : PubMed/NCBI
25	He ZL, Zheng H, Lin H, Miao XY and Zhong DW: Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol. 15:4177–4182. 2009. View Article : Google Scholar : PubMed/NCBI
26	Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M and Kristiansen G: Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate. 60:240–245. 2004. View Article : Google Scholar : PubMed/NCBI
27	Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M and Denkert C: Polo-like kinase isoforms in breast cancer: Expression patterns and prognostic implications. Virchows Arch. 446:442–450. 2005. View Article : Google Scholar : PubMed/NCBI
28	King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM and Meek DW: Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Res. 14:R402012. View Article : Google Scholar : PubMed/NCBI
29	Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M, Dietel M and Hauptmann S: Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer. 90:815–821. 2004. View Article : Google Scholar : PubMed/NCBI
30	Wang ZX, Xue D, Liu ZL, Lu BB, Bian HB, Pan X and Yin YM: Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int J Biochem Cell Biol. 44:200–210. 2012. View Article : Google Scholar : PubMed/NCBI
31	Weiß L and Efferth T: Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol. 1:382012. View Article : Google Scholar : PubMed/NCBI
32	Yim H: Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs. 24:999–1006. 2013. View Article : Google Scholar : PubMed/NCBI
33	Hamanaka R, Maloid S, Smith MR, O'Connell CD, Longo DL and Ferris DK: Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ. 5:249–257. 1994.PubMed/NCBI
34	Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 11:359–377. 1957. View Article : Google Scholar : PubMed/NCBI
35	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell. Hoboken, NJ: 2009.
36	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
37	Halon A, Donizy P, Surowiak P and Matkowski R: ERM/Rho protein expression in ductal breast cancer: A 15 year follow-up. Cell Oncol (Dordr). 36:181–190. 2013. View Article : Google Scholar : PubMed/NCBI
38	Fitzgibbons PL1, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, et al: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 124:966–978. 2000.PubMed/NCBI
39	Degenhardt Y and Lampkin T: Targeting Polo-like kinase in cancer therapy. Clin Cancer Res. 16:384–389. 2010. View Article : Google Scholar : PubMed/NCBI
40	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
41	Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J and Kallioniemi OP: Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer. 21:177–184. 1998. View Article : Google Scholar : PubMed/NCBI